IRVINE, CA, February 11, 2010 -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves and hemodynamic monitoring, announced today that the Appellate Court of Düsseldorf, Germany, has affirmed a lower court decision that CoreValve does not infringe Edwards' German patent for its transcatheter heart valve technology. The ruling has no effect on sales of the Edwards SAPIEN transcatheter valve in Germany or any other country.

"While we are disappointed by this decision on infringement, we will continue to rigorously enforce our leading intellectual property portfolio in this field. We look forward to the trial on the U.S. Andersen patents beginning next month," said Larry L. Wood, Edwards' corporate vice president, transcatheter valve replacement.

Last month, the Federal Patent Court in Munich, Germany, upheld the validity of Edwards' patent for transcatheter valve technology and Edwards succeeded in having CoreValve's invalidity claims dismissed on all grounds.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring, with more than five decades of experience in partnering with clinicians to develop life-saving innovations. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company's global brands include Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, Magna, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.